A detailed history of Deka Bank Deutsche Girozentrale transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 15,800 shares of PTGX stock, worth $708,314. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,800
Previous 15,800 -0.0%
Holding current value
$708,314
Previous $555,000 27.75%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 28, 2022

BUY
$23.34 - $36.08 $32,676 - $50,512
1,400 Added 9.72%
15,800 $378,000
Q4 2021

Feb 02, 2022

BUY
$17.63 - $37.1 $7,052 - $14,840
400 Added 2.86%
14,400 $439,000
Q4 2020

Mar 12, 2021

BUY
$18.49 - $25.13 $258,859 - $351,820
14,000 New
14,000 $300,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.2B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Deka Bank Deutsche Girozentrale Portfolio

Follow Deka Bank Deutsche Girozentrale and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.